Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

May 15, 2024

https://www.globenewswire.com/news-release/2024/05/15/2882744/0/en/Phio-Pharmaceuticals-Announces-Completion-of-Dosing-in-First-Patient-Cohort-in-PH-762-Phase-1b-Dose-Escalation-Study.html

–PH-762 is Phio’s lead product candidate

-Screening on the next cohort is on-going

MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced progress on its Phase 1b clinical study for their lead compound PH-762.   Dosing of the first cohort of patients was completed and screening for the next dose cohort is on-going.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.